Clinical studies have become increasingly virtual because of COVID-19. How has this affected the way the FDA inspects clinical trials? Join Darshan Kulkarni as he talks with former FDA auditor Patrick Stone about his experience investigating sites...
What is an FDA warning letter, and how should your company respond once it has received one? In today's episode, Darshan Kulkarni talks with former FDA inspector Patrick Stone about the auditing process in compounding pharmacies, and how companies...
Will COVID-19 make the practice of virtual monitoring more commonplace in healthcare? Join Darshan Kulkarni as he talks with former FDA auditor Patrick Stone about how auditing is becoming virtual. Plus, we’ll discuss whether the FDA might end up...
